Vivesto AB (VIVE) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.039x

Based on the latest financial reports, Vivesto AB (VIVE) has a cash flow conversion efficiency ratio of -0.039x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.46 Million ≈ $-695.20K USD) by net assets (Skr166.56 Million ≈ $17.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Vivesto AB liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Vivesto AB - Cash Flow Conversion Efficiency Trend (2004–2025)

This chart illustrates how Vivesto AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Vivesto AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Vivesto AB ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Artemis Resources Ltd
AU:ARV
-0.059x
Kiora Pharmaceuticals Inc
NASDAQ:KPRX
-0.227x
Progressive Impact Corporation Bhd
KLSE:7201
0.520x
SSH GROUP LTD
F:JRSA
N/A
BARRAMUNDI GROUP PTE. LTD
F:95Z
N/A
SL Private Equity
LSE:SLPE
-0.001x
Patriot Resources Ltd
AU:PAT
0.050x
B.A.G Films and Media Limited
NSE:BAGFILMS
-0.017x

Annual Cash Flow Conversion Efficiency for Vivesto AB (2004–2025)

The table below shows the annual cash flow conversion efficiency of Vivesto AB from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see VIVE market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr124.58 Million
≈ $13.41 Million
Skr-33.96 Million
≈ $-3.65 Million
-0.273x +8.64%
2024-12-31 Skr158.33 Million
≈ $17.04 Million
Skr-47.25 Million
≈ $-5.08 Million
-0.298x +14.14%
2023-12-31 Skr197.80 Million
≈ $21.29 Million
Skr-68.74 Million
≈ $-7.40 Million
-0.348x -40.46%
2022-12-31 Skr325.42 Million
≈ $35.02 Million
Skr-80.52 Million
≈ $-8.66 Million
-0.247x +6.56%
2021-12-31 Skr549.71 Million
≈ $59.16 Million
Skr-145.56 Million
≈ $-15.67 Million
-0.265x +11.23%
2020-12-31 Skr686.74 Million
≈ $73.90 Million
Skr-204.86 Million
≈ $-22.05 Million
-0.298x -3460.04%
2019-12-31 Skr819.39 Million
≈ $88.18 Million
Skr-6.87 Million
≈ $-738.89K
-0.008x +97.01%
2018-12-31 Skr424.05 Million
≈ $45.63 Million
Skr-118.84 Million
≈ $-12.79 Million
-0.280x +21.79%
2017-12-31 Skr345.04 Million
≈ $37.13 Million
Skr-123.63 Million
≈ $-13.30 Million
-0.358x +19.08%
2016-12-31 Skr300.37 Million
≈ $32.32 Million
Skr-133.01 Million
≈ $-14.31 Million
-0.443x -12.69%
2015-12-31 Skr326.05 Million
≈ $35.09 Million
Skr-128.13 Million
≈ $-13.79 Million
-0.393x -37.13%
2014-12-31 Skr375.71 Million
≈ $40.43 Million
Skr-107.67 Million
≈ $-11.59 Million
-0.287x +7.04%
2013-12-31 Skr281.91 Million
≈ $30.34 Million
Skr-86.90 Million
≈ $-9.35 Million
-0.308x -41.47%
2012-12-31 Skr319.15 Million
≈ $34.35 Million
Skr-69.54 Million
≈ $-7.48 Million
-0.218x -13.63%
2011-12-31 Skr273.47 Million
≈ $29.43 Million
Skr-52.44 Million
≈ $-5.64 Million
-0.192x +2.07%
2010-12-31 Skr294.17 Million
≈ $31.66 Million
Skr-57.60 Million
≈ $-6.20 Million
-0.196x -147.13%
2009-12-31 Skr141.80 Million
≈ $15.26 Million
Skr-11.23 Million
≈ $-1.21 Million
-0.079x -133.97%
2008-12-31 Skr61.21 Million
≈ $6.59 Million
Skr14.28 Million
≈ $1.54 Million
0.233x +167864.83%
2007-12-31 Skr64.81 Million
≈ $6.97 Million
Skr9.00K
≈ $968.54
0.000x +100.07%
2006-12-31 Skr110.30 Million
≈ $11.87 Million
Skr-22.73 Million
≈ $-2.45 Million
-0.206x -7.71%
2005-12-31 Skr58.90 Million
≈ $6.34 Million
Skr-11.27 Million
≈ $-1.21 Million
-0.191x -192.02%
2004-12-31 Skr31.40 Million
≈ $3.38 Million
Skr6.53 Million
≈ $702.68K
0.208x --

About Vivesto AB

ST:VIVE Sweden Drug Manufacturers - Specialty & Generic
Market Cap
$10.66 Million
Skr99.09 Million SEK
Market Cap Rank
#26876 Global
#589 in Sweden
Share Price
Skr8.95
Change (1 day)
+1.70%
52-Week Range
Skr0.08 - Skr17.00
All Time High
Skr17.00
About

Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixi… Read more